Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,064 Hematology
clinical trials

Hemophilia B Clinical Trial
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Hemophilia A or B Clinical Trial
PF-06741086 Long-term Treatment in Severe Hemophilia
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Colorado Denver Hemophilia & Thrombosis Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Status: Enrolling, Phase I, II
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
Status: Enrolling, Phase II
Updated: 12/31/1969
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Status: Enrolling, Phase II
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Status: Enrolling, Phase II
Updated: 12/31/1969
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Status: Enrolling, Phase II
Updated: 12/31/1969
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Epigenetic Reprogramming in Relapse/Refractory AML
Status: Enrolling, Phase I
Updated: 12/31/1969
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Epigenetic Reprogramming in Relapse/Refractory AML
Status: Enrolling, Phase I
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Epigenetic Reprogramming in Relapse/Refractory AML
Status: Enrolling, Phase I
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Epigenetic Reprogramming in Relapse/Refractory AML
Status: Enrolling, Phase I
Updated: 12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Epigenetic Reprogramming in Relapse/Refractory AML
Status: Enrolling, Phase I
Updated: 12/31/1969
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Epigenetic Reprogramming in Relapse/Refractory AML
Status: Enrolling, Phase I
Updated: 12/31/1969
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Hematology Clinical Trial
Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ Depletion for Patients With BMF
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology Clinical Trial
ATHN 7: Hemophilia Natural History Study
Status: Enrolling, Phase
Updated: 12/31/1969
Weill Cornell Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Hematology Clinical Trial
ATHN 7: Hemophilia Natural History Study
Status: Enrolling, Phase
Updated: 12/31/1969
Hemophilia Center of Western Pennsylvania
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Southwest Oncology PC
mi
from
Durango, CO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Swedish Medical Center-Edmonds
mi
from
Edmonds, WA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Elizabeth Hospital
mi
from
Enumclaw, WA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Fruitland
mi
from
Fruitland, ID
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Wayne Memorial Hospital
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Benefis Healthcare- Sletten Cancer Institute
mi
from
Great Falls, MT
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
CHI Saint Vincent Cancer Center Hot Springs
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Swedish Cancer Institute-Issaquah
mi
from
Issaquah, WA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
CHI Health Good Samaritan
mi
from
Kearney, NE
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Regional Cancer System-Lacey
mi
from
Lacey, WA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Lakewood
mi
from
Lakewood, CO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Longmont United Hospital
mi
from
Longmont, CO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Longmont
mi
from
Longmont, CO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Health Partners Inc
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Parker Adventist Hospital
mi
from
Parker, CO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente Northwest
mi
from
Portland, OR
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Kootenai Cancer Center
mi
from
Post Falls, ID
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Springfield Clinic
mi
from
Springfield, IL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Clinical Trial
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
SWOG
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN
Status: Enrolling, Phase I
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Status: Enrolling, Phase II
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Fabry Disease Clinical Trial
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
Status: Enrolling, Phase III
Updated: 12/31/1969
Infusion Associates
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
Status: Enrolling, Phase II
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
Status: Enrolling, Phase II
Updated: 12/31/1969
Brigham and Women Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling, Phase
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Graft-versus-host Disease (GVHD) Clinical Trial
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling, Phase
Updated: 12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KS
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Autoimmune Hemolytic Anemia Clinical Trial
A Study of Parsaclisib in Participants With Autoimmune Hemolytic Anemia
Status: Enrolling, Phase II
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
Status: Enrolling, Phase
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
Status: Enrolling, Phase
Updated: 12/31/1969
Michigan State University Center for Bleeding Disorders & Clotting Disorders
mi
from
East Lansing, MI
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
Status: Enrolling, Phase
Updated: 12/31/1969
Children's Mercy Hospital - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Hemophilia A Clinical Trial
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
Status: Enrolling, Phase
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology, Other Clinical Trial
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Status: Enrolling, Phase
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases Clinical Trial
Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
Status: Enrolling, Phase
Updated: 12/31/1969
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Smoldering Multiple Myeloma Clinical Trial
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
Status: Enrolling, Phase II
Updated: 12/31/1969
Weill Cornell Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Smoldering Multiple Myeloma Clinical Trial
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KS
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy
Status: Enrolling, Phase II
Updated: 12/31/1969
Franciscan Physician Network Oncology And Hematology Specialists
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hematology, Nephrology / Urology, Other Clinical Trial
Embosphere® PROstate Post Market Study
Status: Enrolling, Phase IV
Updated: 12/31/1969
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Regional Cancer System-Aberdeen
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Community Hospital of Anaconda
mi
from
Anaconda, MT
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Alaska Oncology and Hematology LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Anchorage Oncology Centre
mi
from
Anchorage, AK
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare - Canton
mi
from
Canton, IL
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Kootenai Medical Center
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Penrose
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Bay Area Hospital
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Endocrinology, Gastroenterology, Hematology Clinical Trial
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Status: Enrolling, Phase II
Updated: 12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Lineberger Comprehensive Cancer Center, University of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Oregon Health and Science University Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Acute Myelogenous Leukemia Clinical Trial
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
Status: Enrolling, Phase I
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Valley Children's Hospital
mi
from
Madera, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cardon Children's Medical Center
mi
from
Mesa, AZ
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Steven & Alexandra Cohen Children's Medical Center of New York
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Status: Enrolling, Phase III
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
1 … 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 … 121